Azenta (AZTA) Q1 2026 earnings review
Transformation Hits a Speed Bump
Azenta's first quarter of fiscal 2026 interrupted the recent narrative of operational turnaround. While the company finally signed a deal to divest the B Medical Systems distraction, core operational execution faltered. Revenue declined 1% organically, and Adjusted EBITDA margin compressed significantly—falling from 13.0% in the prior quarter to 8.5%—due to rework costs on automated stores and lost leverage. Despite this slow start, management reiterated full-year guidance, effectively betting the entire year's success on a steep second-half recovery.
🐂 Bull Case
The definitive agreement to sell B Medical Systems for $63M (closing by March 2026) removes a significant drag on management attention and profitability, allowing a cleaner focus on core Life Sciences.
The balance sheet remains a fortress with $571M in cash and marketable securities. Combined with the upcoming B Medical proceeds, Azenta has substantial dry powder for buybacks or disciplined M&A.
🐻 Bear Case
Gross margins contracted 360 basis points sequentially, driven partly by 'costs related to rework on several Automated Stores projects.' This points to operational sloppiness in the core hardware business.
By reiterating FY26 guidance (3-5% growth, ~300bps margin expansion) after a negative growth Q1 with 8.5% margins, management has created a 'hockey stick' projection. H2 must perform near-perfectly to hit these targets.
⚖️ Verdict: 🔴
Bearish. The B Medical sale is a positive step, but the core business regressed in Q1. Relying on a massive back-half ramp to meet guidance increases risk significantly, especially with self-inflicted execution wounds in manufacturing.
Key Themes
Execution Issues Hit Margins
Reversing. After a year of steady margin improvement driven by the 'Azenta Business System,' execution slipped. Non-GAAP Gross Margin fell to 44.1% from 47.7% a year ago and 46.7% last quarter. Management explicitly cited 'costs related to rework on several Automated Stores projects.' This operational failure accounted for a significant portion of the margin miss.
Organic Growth Stagnation
Decelerating. Organic revenue declined 1% YoY, down from +4% in the prior quarter. Sample Management Solutions (the core hardware/storage business) declined 2% organically due to lower Automated Stores revenue. While Multiomics was flat, it failed to provide the necessary offset. The macro environment remains hesitant, particularly for large capital purchases.
B Medical Exit
Azenta entered a definitive agreement to sell B Medical Systems for $63M. While this price is likely a fraction of the original acquisition cost (evidenced by recent impairments), the divestiture is a strategic positive. It stops the bleeding from discontinued operations (which lost $10.2M this quarter alone) and simplifies the narrative.
Multiomics Mix Shift Pressure
While Multiomics revenue was up 1% reported, the mix remains a headwind. Growth in Next Gen Sequencing (NGS) and Gene Synthesis is being offset by the structural decline of higher-margin Sanger Sequencing. This mix shift contributed to lost cost leverage in the quarter.
Balance Sheet Optionality
The company ended the quarter with $571M in liquidity. A new $250M share repurchase program was authorized in December 2025, though no shares have been bought yet. With the stock under pressure from mixed results, aggressive buybacks could provide a floor.
Other KPIs
Reversing. Flat year-over-year and down from $86M in the prior quarter. Organic revenue declined 2%, driven by lower Automated Stores and Cryogenic Systems sales. This segment is highly sensitive to customer CapEx cycles.
Decelerating. Down from $0.12 in the prior year and $0.21 in the prior quarter. The decline reflects the compression in operating margins, partially shielded by interest income ($5M).
Stable. Positive generation despite the earnings miss, driven by working capital management. Operating cash flow was $21M vs CapEx of $6M.
Guidance
Accelerating vs Current. Management reiterated this range relative to FY25. Given Q1 was -1%, this implies the remaining three quarters must average ~5-7% growth. This suggests a heavy reliance on a second-half recovery in instrument/store orders.
Accelerating. Reiterated target of ~300 bps expansion over FY25 (approx 11.2%). This implies a full-year target of ~14.2%. With Q1 coming in at 8.5%, the exit rate for the year likely needs to be in the high-teens, creating substantial execution risk.
Key Questions
Rework Costs Nature
The 'rework on several Automated Stores projects' significantly impacted margins. Is this a one-time containment of a specific quality issue, or indicative of a broader systemic problem in manufacturing/deployment?
Guidance Bridge
With Q1 showing negative organic growth and single-digit EBITDA margins, can you provide a specific bridge to the full-year targets? What specific backlog or order visibility supports the massive implied ramp in H2?
Capital Allocation Speed
With $571M in cash and the B Medical sale closing soon, why were zero shares repurchased in Q1 despite the new $250M authorization and the share price weakness?